|
|
|
|
|
Triamterene
drug data and news
Triamterene drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Triamterene | ||
| Brand Names/Synonyms | Ademin; Ademine; Diren; Ditak; Diucelpin; Diurene; Dyazide; Dyren; Dyrenium; Dytac; Jatropur; Maxzide; Maxzide-25; Noridil; Noridyl; Pterofen; Pterophene; SK&F 8542; SKF 8542; Taturil; Teriam; Teridin; Tri-Span; Triampur; Triamteren; Triamterene; Triamteril; Triamteril Complex; Trispan; Triteren; Urocaudal | ||
| Indication | For the treatment of oedema in congestive cardiac failure and renal and hepatic disease used with or without other diuretics to preserve potassium. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Triamterene, a relatively weak, potassium-sparing distal tubule diuretic and antihypertensive, is used in the management of hypokalemia. Triamterene is similar in action to amiloride but, unlike amiloride, increases the urinary excretion of magnesium. | ||
| Mechanism Of Action | Triamterene interferes with sodium reabsorption in the distal renal tubule by inhibiting sodium transport mechanisms directly. Specifically it inhibits the Na+/K+/2Cl- co-transporter. The result is an electrical-potential difference across the membrane that blocks the passive distal tubular secretion of potassium. Relative to other diuretics, Triamterene has a unique mode of action as it inhibits the reabsorption of sodium ions in exchange for potassium and hydrogen ions at that segment of the distal tubule under the control of adrenal mineralocorticoids (especially aldosterone). | ||
| Triamterene News (When available) |
| ||
| Dosage Forms | TABLET | ||
| Drug_Category | Diuretics; Potassium-sparing Diuretics; ATC:C03DB02 | ||
| Absorption | Triamterene is rapidly absorbed, with somewhat less than 50% of the oral dose reaching the urine. | ||
| Interactions |
Interactions for Triamterene: Caution should be used when lithium and diuretics are used concomitantly because diuretic-induced sodium loss may reduce the renal clearance of lithium and increase serum lithium levels with risk of lithium toxicity. Patients receiving such combined therapy should have serum lithium levels monitored closely and the lithium dosage adjusted if necessary. A possible interaction resulting in acute renal failure has been reported in a few subjects when indomethacin, a nonsteroidal anti-inflammatory agent, was given with triamterene. Caution is advised in administering nonsteroidal anti-inflammatory agents with triamterene. The effects of the following drugs may be potentiated when given together with triamterene: antihypertensive medication, other diuretics, preanesthetic and anesthetic agents, skeletal muscle relaxants (nondepolarizing). Potassium-sparing agents should be used with caution in conjunction with angiotensin-converting enzyme (ACE) inhibitors due to an increased risk of hyperkalemia. The following agents, given together with triamterene, may promote serum potassium accumulation and possibly result in hyperkalemia because of the potassium-sparing nature of triamterene, especially in patients with renal insufficiency: blood from blood bank (may contain up to 30 mEq of potassium per liter of plasma or up to 65 mEq per liter of whole blood when stored for more than 10 days); low-salt milk (may contain up to 60 mEq of potassium per liter); potassium-containing medications (such as parenteral penicillin G potassium); salt substitutes (most contain substantial amounts of potassium). Triamterene may raise blood glucose levels; for adult-onset diabetes, dosage adjustments of hypoglycemic agents may be necessary during and after therapy; concurrent use with chlorpropamide may increase the risk of severe hyponatremia. Drug/Laboratory Test Interactions Triamterene and quinidine have similar fluorescence spectra; thus, triamterene will interfere with the fluorescent measurement of quinidine. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 6-phenylpteridine-2,4,7-triamine | ||
| Chemical Formula | C12H11N7 | ||
| Molecular Weight | 253.263 g/mol | ||
| Smiles String | C1=CC=C(C=C1)C2=NC3=C(N=C2N)N=C(N=C3N)N | ||
| Melting Point | 316 °C | ||
| Water Solubility | <0.1 g/100 mL | ||
| State | Powder | ||
| LogP/Hphobicity | 0.03 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Triamterene is primarily metabolized to the sulfate conjugate of hydroxytriamterene. Both the plasma and urine levels of this metabolite greatly exceed triamterene levels. | ||
| Half Life | Not Available | ||
| Protein Binding [%] | 97% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Triamterene.html http://www.rxlist.com/cgi/generic/triamterine.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00079 | ||
| CAS Registry Number | 396-01-0 | ||
| KEGG Compound ID | C07161 | ||
| PubChem ID | SID:153028 | ||
| PharmGKB ID | PA451752 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 1919563 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |